The round was led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE: OSCR), Ryan Fukushima, COO of Tempus, and others. Leading researchers from OpenAI and DeepMind also participated.

Ataraxis is an AI precision medicine company transforming patient outcomes through the power of artificial intelligence. Backed by leading investors AIX Ventures, Floating Point, Bertelsmann Investments, Thiel Bio, Founders Fund, Giant Ventures, and Obvious Ventures, the company is addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Ataraxis' first clinically validated offering, Ataraxis Breast, is the world's first AI-native prognostic/predictive platform for breast cancer and provides greater accuracy than standard of care genomic assays.